MARKET NEWS

Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
BriaCell Secures License for Promising Novel Anti-Cancer Agent
US Patent Issued to HCW Biologics for Foundational Platform Technology
Ocuphire Extends US Patent Protection for Late-Stage Drug Candidate for Reversal of Mydriasis by 5 More Years Into 2039
Athira Pharma Presents Data From ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Evonik Health Care is a global innovation hub for the world’s leading life science companies. We support customers along the entire product cycle from early development to commercial manufacturing. Our system solutions are backed by the scientific excellence of our interdisciplinary and diverse teams. As an integrated CDMO, Evonik Health Care has been a leader for advanced drug delivery for many decades. It is also one of the world’s largest contract manufacturers of high potency APIs (HPAPIs) and active pharmaceutical ingredients (APIs) that require complex chemistry and multiple-step syntheses. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Rigel Pharmaceuticals & Forma Therapeutics Announce Licensing Agreement for Novel Mutant IDH1 Inhibitor

Rigel Pharmaceuticals & Forma Therapeutics Announce Licensing Agreement for Novel Mutant IDH1 Inhibitor

Rigel Pharmaceuticals, Inc. and Forma Therapeutics, Inc. recently announced they have entered into an exclusive, worldwide license agreement to develop, manufacture, and commercialize….

PolyPid Announces Exclusive Licensing Agreement With Advanz Pharma

PolyPid Announces Exclusive Licensing Agreement With Advanz Pharma

PolyPid Ltd. recently announced it has entered into an exclusive licensing agreement with ADVANZ PHARMA Corp.  for the commercialization of its lead drug candidate, D-PLEX100 for the prevention of….

New Lipid Facility at Evonik’s Site in Hanau to Produce Clinical & Launch Quantities of Lipids for Innovative Medicines

New Lipid Facility at Evonik’s Site in Hanau to Produce Clinical & Launch Quantities of Lipids for Innovative Medicines

Evonik is building a new cGMP facility to manufacture lipids for clinical development and launch of innovative medicines. The new cGMP lipid launch facility is located in….

SCHOTT Establishes Stand-Alone Company for its Pharma Business to Promote Further Growth

SCHOTT Establishes Stand-Alone Company for its Pharma Business to Promote Further Growth

SCHOTT has legally established a stand-alone company for its pharma business to advance its growth strategy. As a pioneer in pharma drug containment and system solutions, the international technology….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….

  WHITEPAPERS & WEBINARS

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges

Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing …

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations. It shows the over-additive effect of using two excipients together and addresses how excipients’ viscosity-reducing ability depends on pH. The results show the effect of protein viscosity on …

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

Nanoparticles offer multi-functional capabilities that include the ability to be tracked within the body, deliver a specific compound at a controlled rate, target a particular location, and remotely kill cells once in place due to which their use as drug …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 17 – Transdermal/Topical Delivery
August 24 – Drug Delivery